-
Tytuł:
-
Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality.
-
Autorzy:
-
Anderson, Simon G.
Hutchings, David C.
Woodward, Mark
Rahimi, Kazem
Rutter, Martin K.
Kirby, Mike
Hackett, Geoff
Trafford, Andrew W.
Heald, Adrian H.
-
Temat:
-
TYPE 2 diabetes treatment
PHOSPHODIESTERASE-5 inhibitors
IMPOTENCE
CARDIOVASCULAR disease related mortality
CARDIOVASCULAR diseases risk factors
THERAPEUTICS
CARDIOVASCULAR disease diagnosis
MYOCARDIAL infarction diagnosis
MYOCARDIAL infarction-related mortality
TYPE 2 diabetes diagnosis
PHOSPHODIESTERASE inhibitors
CHI-squared test
DATABASES
CAUSES of death
FAMILY medicine
MULTIVARIATE analysis
TYPE 2 diabetes
PROBABILITY theory
REGRESSION analysis
RESEARCH funding
RISK assessment
TIME
LOGISTIC regression analysis
TREATMENT effectiveness
RETROSPECTIVE studies
KAPLAN-Meier estimator
DIAGNOSIS
-
Źródło:
-
Heart; 11/1/2016, Vol. 102 Issue 21, p1750-1756, 7p, 2 Charts, 4 Graphs
-
Terminy geograficzne:
-
ENGLAND
-
Objective: Experimental evidence has shown potential cardioprotective actions of phosphodiesterase type-5 inhibitors (PDE5is). We investigated whether PDE5i use in patients with type 2 diabetes, with high-attendant cardiovascular risk, was associated with altered mortality in a retrospective cohort study.Research Design and Methods: Between January 2007 and May 2015, 5956 men aged 40-89 years diagnosed with type 2 diabetes before 2007 were identified from anonymised electronic health records of 42 general practices in Cheshire, UK, and were followed for 7.5 years. HRs from multivariable survival (accelerated failure time, Weibull) models were used to describe the association between on-demand PDE5i use and all-cause mortality.DC1SM110.1136/heartjnl-2015-309223.supp1Supplementary appendix RESULTS: Compared with non-users, men who are prescribed PDE5is (n=1359) experienced lower percentage of deaths during follow-up (19.1% vs 23.8%) and lower risk of all-cause mortality (unadjusted HR=0.69 (95% CI: 0.64 to 0.79); p<0.001)). The reduction in risk of mortality (HR=0.54 (0.36 to 0.80); p=0.002) remained after adjusting for age, estimated glomerular filtration rate, smoking status, prior cerebrovascular accident (CVA) hypertension, prior myocardial infarction (MI), systolic blood pressure, use of statin, metformin, aspirin and β-blocker medication. PDE5i users had lower rates of incident MI (incidence rate ratio (0.62 (0.49 to 0.80), p<0.0001) with lower mortality (25.7% vs 40.1% deaths; age-adjusted HR=0.60 (0.54 to 0.69); p=0.001) compared with non-users within this subgroup.Conclusion: In a population of men with type 2 diabetes, use of PDE5is was associated with lower risk of overall mortality and mortality in those with a history of acute MI. [ABSTRACT FROM AUTHOR]
Copyright of Heart is the property of BMJ Publishing Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)